Manara - Qatar Research Repository
Browse
10.1016_j.crwh.2019.e00162.pdf (387.18 kB)

Severe rebound disease activity after fingolimod withdrawal in a pregnant woman with multiple sclerosis managed with rituximab: A case study

Download (387.18 kB)
journal contribution
submitted on 2024-03-05, 06:55 and posted on 2024-03-05, 06:55 authored by Beatriz Canibaño, Musab Ali, Boulenouar Mesraoua, Gayane Melikyan, Hasan Al Hail, Faiza Ibrahim, Yolande Hanssens, Dirk Deleu

Although pregnancy is potentially protective against relapses of multiple sclerosis, severe rebound of disease activity after withdrawal of fingolimod may occur. We report a woman with multiple sclerosis who discontinued fingolimod in the first month of her pregnancy. She developed severe disease rebound which responded poorly to steroids. She was started on rituximab, which was continued during the rest of her pregnancy and beyond. Rituximab appeared safe and well tolerated by both mother and infant, and could be considered in pregnancy for those patients with multiple sclerosis who are at high risk of gestational and postpartum relapse.

Other Information

Published in: Case Reports in Women's Health
License: http://creativecommons.org/licenses/by-nc-nd/4.0/
See article on publisher's website: https://dx.doi.org/10.1016/j.crwh.2019.e00162

Funding

Open Access funding provided by the Qatar National Library.

History

Language

  • English

Publisher

Elsevier

Publication Year

  • 2020

License statement

This Item is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Institution affiliated with

  • Hamad Medical Corporation
  • Neuroscience Institute - HMC

Usage metrics

    Hamad Medical Corporation

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC